About this Journal Submit a Manuscript Table of Contents 
Case Reports in Psychiatry
Volume 2012 (2012), Article ID 642752, 4 pages
http://dx.doi.org/10.1155/2012/642752
Case Report

Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report

Domenico De Berardis,1,2 Nicola Serroni,1 Stefano Marini,1,2 Giovanni Martinotti,2 Francesca Ferri,1 Gaetano Callista,3 Raffaella La Rovere,3 Francesco Saverio Moschetta,1 and Massimo Di Giannantonio2

1NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4, 64100 Teramo, Italy
2Department of Neurosciences and Imaging, Chair of Psychiatry, University “G. D’Annunzio”, 66100 Chieti, Italy
3NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “Maria SS. dello Splendore”, ASL 4, 64021 Giulianova, Italy

Received 16 July 2012; Accepted 18 September 2012

Academic Editors: E. Jönsson and M. Kluge

Copyright © 2012 Domenico De Berardis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. De Berardis, D. Campanella, F. Gambi et al., “Insight and alexithymia in adult outpatients with obsessive-compulsive disorder,” European Archives of Psychiatry and Clinical Neuroscience, vol. 255, no. 5, pp. 350–358, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Abudy, A. Juven-Wetzler, and J. Zohar, “Pharmacological management of treatment-resistant obsessive-compulsive disorder,” CNS Drugs, vol. 25, no. 7, pp. 585–596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. De Berardis, G. Di Iorio, T. Acciavatti et al., “The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.,” CNS & Neurological Disorders Drug Targets, vol. 10, no. 1, pp. 119–132, 2011. View at Google Scholar · View at Scopus
  4. C. De Bodinat, B. Guardiola-Lemaitre, E. Mocaër, P. Renard, C. Muñoz, and M. J. Millan, “Agomelatine, the first melatonergic antidepressant: discovery, characterization and development,” Nature Reviews Drug Discovery, vol. 9, no. 8, pp. 628–642, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Di Giannantonio, G. Di Iorio, R. Guglielmo et al., “Major depressive disorder, anhedonia and agomelatine: an open-label study,” Journal of Biological Regulators and Homeostatic Agents, vol. 25, no. 1, pp. 109–114, 2011. View at Google Scholar · View at Scopus
  6. G. Martinotti, G. Sepede, F. Gambi, et al., “Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study,” Journal of Clinical Psychopharmacology, vol. 32, no. 4, pp. 487–491, 2012. View at Google Scholar
  7. I. B. Hickie and N. L. Rogers, “Novel melatonin-based therapies: potential advances in the treatment of major depression,” The Lancet, vol. 378, no. 9791, pp. 621–631, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Fornaro, “Switching from serotonin reuptake inhibitors to agomelatine in patients with refractoryobsessive-compulsive disorder: a 3 month follow-up case series,” Annals of General Psychiatry, vol. 10, article 5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. De Berardis, N. Serroni, D. Campanella, et al., “A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy,” Journal of Clinical Psychopharmacology, vol. 32, no. 2, pp. 289–290, 2012. View at Google Scholar
  10. F. F. da Rocha and H. Correa, “Is circadian rhythm disruption important in obsessive-compulsive disorder [OCD]? A case of successful augmentation with agomelatine for the treatment of OCD,” Clinical Neuropharmacology, vol. 34, no. 4, pp. 139–140, 2011. View at Google Scholar
  11. D. L. Ackerman and S. Greenland, “Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder,” Journal of Clinical Psychopharmacology, vol. 22, no. 3, pp. 309–317, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Marazziti, G. Consoli, and S. Baroni, “Past, present and future drugs for the treatment of obsessive-compulsive disorder,” Current Medicinal Chemistry, vol. 17, no. 29, pp. 3410–3421, 2010. View at Google Scholar · View at Scopus
  13. L. L. Von Moltke, D. J. Greenblatt, G. M. Giancarlo, B. W. Granda, J. S. Harmatz, and R. I. Shader, “Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram,” Drug Metabolism and Disposition, vol. 29, no. 8, pp. 1102–1109, 2001. View at Google Scholar · View at Scopus
  14. M. Fornaro, D. Prestia, S. Colicchio, and G. Perugi, “A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation,” Current Neuropharmacology, vol. 8, no. 3, pp. 287–304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Srinivasan, R. Zakaria, Z. Othaman, A. Brzezinski, A. Prasad, and G. M. Brown, “Melatonergic drugs for therapeutic use in insomnia and sleep disturbances of mood disorders,” CNS & Neurological Disorders—Drug Targets, vol. 11, no. 2, pp. 180–189, 2012. View at Google Scholar
  16. K. W. Lange, K. M. Lange, J. Hauser, L. Tucha, and O. Tucha, “Circadian rhythms in obsessive-compulsive disorder,” Journal of Neural Transmission, vol. 119, no. 10, pp. 1077–1083, 2012. View at Google Scholar
  17. S. Mukhopadhyay, N. A. Fineberg, L. M. Drummond et al., “Delayed sleep phase in severe obsessive-compulsive disorder: a systematic case-report survey,” CNS Spectrums, vol. 13, no. 5, pp. 406–413, 2008. View at Google Scholar · View at Scopus
  18. P. Monteleone, F. Catapano, G. Del Buono, and M. Maj, “Circadian rhythms of melatonin, cortisol and prolactin in patients with obsessive-compulsive disorder,” Acta Psychiatrica Scandinavica, vol. 89, no. 6, pp. 411–415, 1994. View at Google Scholar · View at Scopus
  19. D. J. Stein, A. A. Ahokas, and C. De Bodinat, “Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study,” Journal of Clinical Psychopharmacology, vol. 28, no. 5, pp. 561–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. De Berardis, N. Serroni, S. Marini, F. S. Moschetta, G. Martinotti G, and M. Di Giannantonio, “Agomelatine for the treatment of posttraumatic stress disorder: a case report,” Annals of Clinical Psychiatry, vol. 24, no. 3, pp. 241–242, 2012. View at Google Scholar